215544-03-9

Upstream product

• 108741-12-4 ethyl (2S,3R)-2,3-dihydroxy-3-phenylpropanoate 
• 77-76-9 2,2-dimethoxy-propane 
• 108741-14-6 (2R,3S)-ethyl 2,3-dihydroxy-3-phenylpropanoate 
• 4192-77-2 ethyl cinnamate 

Downstream Products

• 153481-85-7 (4R,5S)-2,2-dimethyl-5-phenyl-[1,3]-dioxolane-4-carbaldehyde 
• 104713-12-4 (R)-1-phenylprop-2-en-1-ol 
• 501012-71-1 (4R,5S)-4-(chloromethyl)-2,2-dimethyl-5-phenyl-1,3-dioxolane 
• 4187-87-5 (R)-1-phenyl-2-propyn-1-ol 
• 153609-00-8 (4S,5S)-2,2-dimethyl-4-(hydroxymethyl)-5-phenyl-1,3-dioxolane 

Relevant academic research and scientific papers

Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of potential substrate-specific ERK1/2 inhibitors

A series of analogs of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione, a putative substrate-specific ERK1/2 inhibitor, were synthesized and biologically characterized in human leukemia U937 cells to define its pharmacophore. It was disc

NOREPINEPHRINE TRANSPORTER RADIOTRACERS AND METHODS OF SYNTHESES THEREOF

The present invention provides compounds and radiotracers thereof for locating, diagnosing, identifying, evaluating, detecting or quantitating NET by in vivo imaging. The invention also provides methods for locating, diagnosing, identifying, evaluating, detecting or quantitating NET, using radiotracers of high-affinity or labeled compounds of the invention, which exhibit low toxicity, can cross the blood-brain barrier and, preferably, distinguish among normal and abnormal brains. For example, a radiotracer of the invention can be administered to a patient in an amount suitable for in vivo imaging thereof. Preferably, radiotracers of the invention can also be used to locate, diagnosis, identify, evaluate, detect and quantitate NET in such diseases, disorders, conditions or maladies as, without limitation, depression, anxiety, ADHD and drug dependency.

Preparation of chiral propargylic alcohols from α,β-unsaturated esters

A series of chiral propargylic alcohols with high enantiomeric excess was prepared by asymmetric dihydroxylation of α,β-unsaturated esters, conversion of the diols to 4-(chloromethyl)-1,3-dioxolane intermediates, and base-induced elimination.

Asymmetric syntheses of chiral allylic alcohols

Chiral allylic alcohols 2 can easily be obtained by elimination from iodo ketals 10. These are available from natural sources, or by application of the asymmetric Sharpless dihydroxylation to vinylogous esters 6, subsequent reduction, halogenation and elimination. This protocol allows the synthesis of highly functionalized allylic alcohols, which can be used in asymmetric Claisen rearrangements.